RU2189976C2 - Арилпиримидиновые производные и фармацевтическая композиция - Google Patents

Арилпиримидиновые производные и фармацевтическая композиция Download PDF

Info

Publication number
RU2189976C2
RU2189976C2 RU98123001/04A RU98123001A RU2189976C2 RU 2189976 C2 RU2189976 C2 RU 2189976C2 RU 98123001/04 A RU98123001/04 A RU 98123001/04A RU 98123001 A RU98123001 A RU 98123001A RU 2189976 C2 RU2189976 C2 RU 2189976C2
Authority
RU
Russia
Prior art keywords
alkyl
formula
amino
hydrogen
compound
Prior art date
Application number
RU98123001/04A
Other languages
English (en)
Russian (ru)
Other versions
RU98123001A (ru
Inventor
Джейкоб БЕРДЖЕР
Ли Аллен ФЛИППИН
Роберт ГРИНХАУС
Саул ХАЙМЕ-ФИГУЕРОА
Ваньджоу ЛЮ
Обри Керн МИЛЛЕР
Дейвид Джордж ПУТМАН
Клаус Курт ВЕЙНХАРДТ
Чухай ДЖАО
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU98123001A publication Critical patent/RU98123001A/ru
Application granted granted Critical
Publication of RU2189976C2 publication Critical patent/RU2189976C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU98123001/04A 1996-05-23 1997-05-14 Арилпиримидиновые производные и фармацевтическая композиция RU2189976C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1821896P 1996-05-23 1996-05-23
US60/018218 1996-05-23
US4037797P 1997-03-10 1997-03-10
US60/040377 1997-03-10

Publications (2)

Publication Number Publication Date
RU98123001A RU98123001A (ru) 2000-10-20
RU2189976C2 true RU2189976C2 (ru) 2002-09-27

Family

ID=26690869

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98123001/04A RU2189976C2 (ru) 1996-05-23 1997-05-14 Арилпиримидиновые производные и фармацевтическая композиция

Country Status (31)

Country Link
US (1) US5863924A (https=)
EP (1) EP0901474B1 (https=)
JP (1) JP2001525794A (https=)
KR (1) KR100518101B1 (https=)
CN (1) CN1109675C (https=)
AR (1) AR007253A1 (https=)
AT (1) ATE323682T1 (https=)
AU (1) AU725891B2 (https=)
BR (1) BR9709599A (https=)
CA (1) CA2255705A1 (https=)
CO (1) CO4950514A1 (https=)
CZ (1) CZ291849B6 (https=)
DE (1) DE69735712T2 (https=)
DK (1) DK0901474T3 (https=)
ES (1) ES2262178T3 (https=)
HR (1) HRP970275B1 (https=)
HU (1) HUP9901535A3 (https=)
ID (1) ID16969A (https=)
IL (1) IL127056A (https=)
MA (1) MA26431A1 (https=)
MY (1) MY119181A (https=)
NO (1) NO311800B1 (https=)
NZ (1) NZ332802A (https=)
PT (1) PT901474E (https=)
RU (1) RU2189976C2 (https=)
SA (2) SA97180191B1 (https=)
TR (1) TR199802391T2 (https=)
TW (1) TW440563B (https=)
UY (1) UY24560A1 (https=)
WO (1) WO1997044326A1 (https=)
YU (1) YU53298A (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093934A3 (ru) * 2008-01-24 2009-10-15 Алла Хем, Ллс ЗАМЕЩЕННЫЕ 3-CYЛЬФOНИЛ-[1,2,3]ТPИAЗOЛO[1,5-а] ПИРИМИДИНЫ-АНТОГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, ИХ ПРИМЕНЕНИЕ И ПОЛУЧЕНИЕ
RU2398768C2 (ru) * 2005-02-18 2010-09-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич производные 2-(4-цианофениламино)-пиримидин-оксида
RU2403244C2 (ru) * 2004-09-30 2010-11-10 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5-карбо- или гетероциклические замещенные пиримидины
RU2416604C2 (ru) * 2004-11-15 2011-04-20 Райджел Фармасьютикалз, Инк. Стереоизомерно обогащенные 3-аминокарбонильные бициклогептеновые пиримидиндиамины и их применения
RU2436776C2 (ru) * 2005-09-27 2011-12-20 Айрм Ллк ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
RU2455288C2 (ru) * 2007-08-22 2012-07-10 Айрм Ллк Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
US8372849B2 (en) 2008-04-21 2013-02-12 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
RU2605265C1 (ru) * 2015-10-06 2016-12-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Анальгезирующее и противовоспалительное средство на основе 5-бутил-6-гидрокси-2-метилпиримидин-4(3h)-она

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012151B1 (en) * 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
US6040315A (en) * 1997-10-30 2000-03-21 Day; Charles E. Antacid co-polymer of guanidine and polyethylenimine
DE19844291A1 (de) * 1998-09-18 2000-03-23 Schering Ag Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AU768201B2 (en) * 1999-01-22 2003-12-04 Amgen, Inc. Kinase inhibitors
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
ATE277064T1 (de) 1999-05-26 2004-10-15 Hoffmann La Roche Verfahren zur herstellung von vinylpyrimidinderivaten
DE60005526T2 (de) * 1999-07-30 2004-07-01 Pharmagene Laboratories Ltd. Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
JP4064671B2 (ja) * 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US6444477B1 (en) 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
CA2446980A1 (en) * 2001-05-14 2002-11-21 Argyrios G. Arvanitis Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP2005500294A (ja) * 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
EP1474141A1 (en) * 2002-02-13 2004-11-10 Pharmagene Laboratories Ltd 5-ht2b receptor antagonists
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US20040023981A1 (en) * 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
US20040023978A1 (en) * 2002-07-24 2004-02-05 Yu Ren Active salt forms with tyrosine kinase activity
ES2445208T3 (es) * 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
OA13309A (en) * 2002-12-20 2007-04-13 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2005012263A1 (en) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
ES2320772T3 (es) * 2003-07-25 2009-05-28 Ciba Holding Inc. Uso de 2,4-bis (alquilamino)pirimidinas sustituidas o quinazolinas como agentes antimicrobianos.
BRPI0413018B8 (pt) * 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
JPWO2005040135A1 (ja) * 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
WO2005074643A2 (en) * 2004-01-30 2005-08-18 Smithkline Beecham Corporation Benzamide compounds useful as rock inhibitors
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20080161419A1 (en) 2004-02-20 2008-07-03 Shinobu Akuzawa Prophylactic Antimigraine Agents
WO2005099711A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013165A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
US7820654B2 (en) * 2004-09-23 2010-10-26 Dr. Reddy's Laboratories Ltd. Pyrimidine compounds, process for their preparation and compositions containing them
EP1814878B1 (en) * 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CN101151249B (zh) * 2005-03-31 2011-04-06 辉瑞产品公司 环戊吡啶及四氢喹啉衍生物
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
JP5118029B2 (ja) * 2005-06-14 2013-01-16 タイゲン バイオテクノロジー カンパニー，リミテッド ピリミジン化合物
WO2007036732A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
WO2007062417A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Methods of preparing 2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-yl-pyrimidine and 4-(1-alkylpyrrolidin-2-yl)-2-(1h-imidazol-1-yl)-6-methylpyrimidine derivatives
CN101384549B (zh) 2006-02-20 2011-04-13 安斯泰来制药株式会社 吡咯衍生物或其盐
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
JP2010514688A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー インドール−４−イルピリミジニル−２−イル−アミン誘導体およびサイクリン依存性キナーゼ阻害剤としてのその使用
CA2679126A1 (en) 2007-03-01 2008-09-04 Chugai Seiyaku Kabushiki Kaisha Macrocyclic compound
BRPI0810411B8 (pt) * 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
BRPI0908098A2 (pt) 2008-02-19 2015-08-18 Adolor Corp Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2
CN102438993A (zh) * 2009-05-19 2012-05-02 陶氏益农公司 用于控制真菌的化合物和方法
AU2010339531A1 (en) 2009-12-30 2012-08-23 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
CN102786512A (zh) * 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
US10336768B2 (en) 2014-06-13 2019-07-02 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
CN104725322B (zh) * 2015-02-16 2017-05-24 同济大学 一种2‑胺基嘧啶类化合物及其制备方法
WO2016173438A1 (zh) * 2015-04-29 2016-11-03 南京明德新药研发股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
CN108904503B (zh) * 2018-07-02 2021-09-28 陕西科技大学 6-氯-5-硝基-2,4-二氨基嘧啶在治疗慢性粒细胞白血病药物中的应用
MY209362A (en) * 2019-06-06 2025-07-03 Arcus Biosciences Inc Processes for preparing aminopyrimidine compounds
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
CN114907273B (zh) * 2022-06-09 2025-02-18 乐威医药（江苏）股份有限公司 2-氨基嘧啶-6-芳基化合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965101A (en) * 1973-07-26 1976-06-22 E. R. Squibb & Sons, Inc. 1-(O-Bromo-phenoxyalkyl)-1,2-dihydro-2-iminopyrimidines
US5147876A (en) * 1988-12-29 1992-09-15 Mitsui Petrochemical Industries, Ltd. 2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines, their pharmaceutically acceptable salts, pharmaceutical compositions containing same and their use in the treatment of neurological diseases
RU2014327C1 (ru) * 1987-09-28 1994-06-15 Циба-Гейги АГ Способ получения производных 2-анилинопиримидина
RU2036909C1 (ru) * 1987-12-02 1995-06-09 Пфайзер Инк. Ацилпроизводные гидроксипиримидинов

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535330A (en) * 1968-04-29 1970-10-20 Sandoz Ag 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US5002951A (en) * 1979-03-19 1991-03-26 The Upjohn Company Method for treating bacterial and protozoal infections
US4543248A (en) * 1979-03-19 1985-09-24 The Upjohn Company Method for immunoregulation with 6-aryl pyrimidine compounds
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
GB2056449A (en) * 1979-08-08 1981-03-18 Searle & Co 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides
US4619933A (en) * 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
FR2539741A1 (fr) * 1983-01-21 1984-07-27 Sanofi Sa Composes a noyau heterocyclique diazote, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
US4512993A (en) * 1983-07-25 1985-04-23 Sterling Drug Inc. 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof
US4504482A (en) * 1983-07-28 1985-03-12 Sterling Drug Inc. [5(or 4)-(Pyridinyl)-2-pyrimidinyl]ureas and cardiotonic use thereof
WO1986004583A1 (en) * 1985-02-05 1986-08-14 The Upjohn Company 4-substituted-6-aryl pyrimidine compounds
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
US4929726A (en) * 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
IE63502B1 (en) * 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE4237768A1 (en) * 1991-11-12 1993-05-13 Ciba Geigy Ag New polyarylene ether derivs. with reduced viscosity - used to prepare moulded bodies, foils, fibres and membranes, as matrix resins, adhesives or coating agents or as polymer additives
US5698444A (en) * 1993-12-23 1997-12-16 Eli Lilly And Company Serotonin receptor protein and related nucleic acid compounds
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
AU692090B2 (en) * 1995-04-13 1998-05-28 Taiho Pharmaceutical Co., Ltd. Novel 4,6-diarylpyrimidine derivatives and salts thereof
US5795905A (en) * 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965101A (en) * 1973-07-26 1976-06-22 E. R. Squibb & Sons, Inc. 1-(O-Bromo-phenoxyalkyl)-1,2-dihydro-2-iminopyrimidines
RU2014327C1 (ru) * 1987-09-28 1994-06-15 Циба-Гейги АГ Способ получения производных 2-анилинопиримидина
RU2036909C1 (ru) * 1987-12-02 1995-06-09 Пфайзер Инк. Ацилпроизводные гидроксипиримидинов
US5147876A (en) * 1988-12-29 1992-09-15 Mitsui Petrochemical Industries, Ltd. 2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines, their pharmaceutically acceptable salts, pharmaceutical compositions containing same and their use in the treatment of neurological diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUDESINSKY Z. ET AL. Uber die Darstellung von 2-Sulfanilamido-4-methylpyrimidinen mit einem heterocyclischen Substituenten in 6-Stellung. COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, XP002037181, 1961, v. 26, с.2865-70. *
HOYER D. ET AL. VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin). PHARMACOLOGICAL REVIEWS, XP000602868, 1994, v. 46, no. 2, с.157-203. MARTIN G.R. ET AL. Classification Review. Receptors for 5-Hydroxytryptamine: Current Perspectives on Classification and Nomenclature. NEUROPHARMACOLOGY, XP002037183, 1994, v.33, no. 3/4, с.261-73. *
MARIELLA R.P. ET AL. Preparation of Various Substituted Pyrimidines. cited in the application JOURNAL OF ORGANIC CHEMISTRY, XP002037179, 1960 v. 25, c.647-8, ESSAWY S.A. ET AL. Synthesis and Reactions of 2-Amino-4-Aryl-6-(2'-Methoxynaphthyl) Pyrimidines. EGYPTIAN JOURNAL OF CHEMISTRY, XP002037180, 1994, v 37, no. 4, с.423-31. *
MOKROSZ J.L. et al., Structure-activity relationship -studies of CNS agents. Part 14: Structural requirements for the 5-HT1A and 5-HT2A receptor selectivity of simple 1-(2-pyrimidinyl)piperazine derivatives. PHARMAZIE, XP002037178, 1994, v. 49, no. 11, С. 801-6. *
ЗАГУЛЯЕВА О.А. и др. Синтез метоксиалкилзамещенных 2-аминопиримидинов из гамма-метоксиалкинилкетонов. - Известия Сибирской АН СССР, сер. хим. наук, ХР002037182, 1990, т.4, с.27-31. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2403244C2 (ru) * 2004-09-30 2010-11-10 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5-карбо- или гетероциклические замещенные пиримидины
RU2416604C2 (ru) * 2004-11-15 2011-04-20 Райджел Фармасьютикалз, Инк. Стереоизомерно обогащенные 3-аминокарбонильные бициклогептеновые пиримидиндиамины и их применения
RU2398768C2 (ru) * 2005-02-18 2010-09-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич производные 2-(4-цианофениламино)-пиримидин-оксида
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
RU2436776C2 (ru) * 2005-09-27 2011-12-20 Айрм Ллк ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
RU2455288C2 (ru) * 2007-08-22 2012-07-10 Айрм Ллк Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
WO2009093934A3 (ru) * 2008-01-24 2009-10-15 Алла Хем, Ллс ЗАМЕЩЕННЫЕ 3-CYЛЬФOНИЛ-[1,2,3]ТPИAЗOЛO[1,5-а] ПИРИМИДИНЫ-АНТОГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, ИХ ПРИМЕНЕНИЕ И ПОЛУЧЕНИЕ
US8372849B2 (en) 2008-04-21 2013-02-12 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
RU2605265C1 (ru) * 2015-10-06 2016-12-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Анальгезирующее и противовоспалительное средство на основе 5-бутил-6-гидрокси-2-метилпиримидин-4(3h)-она

Also Published As

Publication number Publication date
JP2001525794A (ja) 2001-12-11
CZ380398A3 (cs) 1999-04-14
HK1020345A1 (en) 2000-04-14
HRP970275B1 (en) 2002-12-31
ID16969A (id) 1997-11-27
IL127056A0 (en) 1999-09-22
US5863924A (en) 1999-01-26
NO985392D0 (no) 1998-11-19
DE69735712D1 (de) 2006-05-24
KR20000015900A (ko) 2000-03-15
UY24560A1 (es) 2000-12-29
PT901474E (pt) 2006-07-31
WO1997044326A1 (en) 1997-11-27
ATE323682T1 (de) 2006-05-15
NZ332802A (en) 2000-07-28
AU2897897A (en) 1997-12-09
NO311800B1 (no) 2002-01-28
ES2262178T3 (es) 2006-11-16
DE69735712T2 (de) 2006-11-30
YU53298A (en) 1999-11-22
TW440563B (en) 2001-06-16
KR100518101B1 (ko) 2005-12-26
BR9709599A (pt) 1999-08-10
HRP970275A2 (en) 1998-04-30
EP0901474B1 (en) 2006-04-19
CN1223641A (zh) 1999-07-21
AU725891B2 (en) 2000-10-26
MY119181A (en) 2005-04-30
CZ291849B6 (cs) 2003-06-18
CO4950514A1 (es) 2000-09-01
SA05260356B1 (ar) 2006-04-25
HUP9901535A2 (hu) 1999-09-28
TR199802391T2 (xx) 1999-02-22
CN1109675C (zh) 2003-05-28
EP0901474A1 (en) 1999-03-17
DK0901474T3 (da) 2006-07-31
MA26431A1 (fr) 2004-12-20
AR007253A1 (es) 1999-10-27
NO985392L (no) 1999-01-25
IL127056A (en) 2003-11-23
CA2255705A1 (en) 1997-11-27
SA97180191B1 (ar) 2006-03-15
HUP9901535A3 (en) 2002-07-29

Similar Documents

Publication Publication Date Title
RU2189976C2 (ru) Арилпиримидиновые производные и фармацевтическая композиция
US5958934A (en) Aryl pyrimidine derivatives and uses thereof
US5952331A (en) Aryl pyrimidine derivatives
KR100258052B1 (ko) 5ht2c-수용체 길항제로서의 피리미딘 유도체 및 이를 포함하는 약물
US7531547B2 (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
KR101025381B1 (ko) Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘
JPH09509188A (ja) 新規なピリミジン誘導体およびその製造方法
EP1321169A1 (en) Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
RU2314305C2 (ru) Производные 4-(тио- или селеноксантен-9-илиден)-пиперидина или акридина, фармацевтическая композиция на их основе и применение
WO2007065449A1 (en) Pyrimidine derivatives and their use as kcnq potassium channels openers
EP1270568A1 (en) 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist
PL190547B1 (pl) Pochodne arylo-pirymidyny, zawierające je kompozycje farmaceutyczne, sposoby ich wytwarzania, oraz ich zastosowanie do wytwarzania środków leczniczych
US7348332B2 (en) (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
SA05260355B1 (ar) مشتقات اريل بيريميدين aryl pyrimidine واستخداماتها
US20030022920A1 (en) 1-Methyl-4- (3-ethoxy-9H-thioxanthene-9-ylidene) -piperidine and its use as 5-HT2B/H1 receptor antagonist

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070515